Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5897)	3/13/2002 4:32:01 PM
From: JMarcus	Read Replies (1) \| Respond to of 52153

At 30 minutes before the close of the market on Monday, EPIX will announce Phase III results in a presentation before the American College of Cardiology. After the market close, they'll host a conference call for investors. <<CAMBRIDGE, Mass.--(BW HealthWire)--March 13, 2002--Phase III clinical trial results of magnetic resonance angiography (MRA) enhanced by EPIX Medical's lead-product in development, MS-325 will be presented at the 2002 American College of Cardiology Annual Scientific Session. ``Results of a Dose-Ranging Diagnostic Trial of Magnetic Resonance Angiography With MS-325, a Blood Pool Contrast Agent, for the Detection of Vascular Occlusive Disease in the Aortoiliac Region'' will be presented by Emile R. Mohler, III, MD on Monday, March 18, 2002 at 3:30 pm EST (Georgia World Congress Center, Hall G). EPIX Medical will host a live webcast of its conference call discussing the Phase III clinical trial results, and providing an update on the MS-325 clinical trial program, at 5:30 pm EST on March 18, 2002. The press release and webcast can be accessed by visiting the EPIX website at www.epixmed.com.>> Looking at the stock chart, you'll see that the stock rebounded sharply starting in November, but has been in a holding pattern (near 52-week high) for the past couple months: quote.yahoo.com Here's what I'd like to believe: 1) The heavy buying in November may have been due in part to leaks from the scientific community about the Phase III trial results. 2) The news on Monday is therefore likely to be good. 3) The stock will rally on the news this Monday and will shoot through the 52-week high. 4) Because there is no resistance above the 52-week high, and because there is a healthy base at the current trading range, the stock will rise into a sustained rally. I hope I'm right. I've been long the stock for a good while. Marc

To: Biomaven who wrote (5897)	3/13/2002 7:03:29 PM
From: Sleepman	Read Replies (1) \| Respond to of 52153

Peter: I am generally a lurker on the board, but have been wanting to ask your opinion about protein production stocks. Specifically, with the cost of antibody and protein production so high, and potential differences between cell lines of production, I have been interested in GZTC. They are putting the genes into the mammary sequences in goats, mice, and cattle and should be able to reliably produce large quantities of consistent protein product throughout the life of the goat (the most common animal used). Do you have any thoughts about this or any other stocks in this part of biotech? Thanks, Dan

To: Biomaven who wrote (5897)	3/13/2002 9:30:02 PM
From: John Metcalf	Read Replies (2) \| Respond to of 52153

I don't know if anyone else follows economic/political events in Japan. To me, they are important because Japan is a large creditor nation, because Asian growth is the most significant in the world and is heavily financed from Japan, and because there are many biotech partnerships with Japanese companies; especially, with those companies listed here. For S&P to say that the Japanese pharmas will not be killed by price roll-backs is a different thing than saying their US/European partners won't be hurt. Of course, my expectation is that yen will decline severely in the next few years. There is deflation, and Japan has the largest proportion of aging population in the world. Will the US follow this path? S&P downplays drug price cuts Standard & Poor's Corp. said Wednesday that the Japanese government's planned cuts in drug reimbursement prices will have a limited impact on its ratings for seven Japanese pharmaceuticals. The U.S.-based credit rating agency's bulletin concerns its short-term debt rating of A-1-plus for Takeda Chemical Industries Ltd., the A-plus-pi long-term rating for Sankyo Co., and the AA-minus-pi long-term rating for Yamanouchi Pharmaceutical Co. Also concerned are the A-pi long-term ratings for Eisai Co., Fujisawa Pharmaceutical Co., and Daiichi Pharmaceutical Co., as well as the BBB-plus-pi long-term rating for Chugai Pharmaceutical Co. Japan's Ministry of Health, Labor and Welfare on Tuesday announced a planned revision in drug reimbursement prices under the National Health Insurance system for fiscal 2002 beginning April 1. The revision will result in an average decrease of 6.3 percent. S&P said the decrease will bring down prices for the drug companies by a range of about mid-5 percent for Fujisawa and upper-7 percent for Daiichi for their drugs listed under the system. But the reduction is unlikely to lead to a substantial deterioration in cash flows at the companies, although it may have a greater impact in the medium and long term, if the government reduces reimbursement prices further, it said. The Japan Times: March 14, 2002 (C) All rights reserved P.S. I know this concept is way too geeky for response from the hot stock seekers.